Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Double-Blind, Parallel-Controlled, Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Conditions
Interventions
HLX13
Yervoy
+1 more
Locations
51
United States
Oncology Physicians Network (OPN) - Los Alamitos /OPN Healthcare
Glendale, California, United States
Los Angeles Cancer Network
Glendale, California, United States
Cancer Specialists of North Florida
Jacksonville, Florida, United States
D&H National Research Centers, LLC
Margate, Florida, United States
Mid Florida Hematology and oncology Center
Orange City, Florida, United States
Florida Clinical Trials Group
Plantation, Florida, United States
Start Date
November 25, 2025
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
March 16, 2026
NCT07493044
NCT07469319
NCT07291076
NCT07365930
NCT07178587
NCT07369505
Lead Sponsor
Shanghai Henlius Biotech
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions